Redmile Group, LLC Regenxbio Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q2 2024

A detailed history of Redmile Group, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,569,802 shares of RGNX stock, worth $40.2 Million. This represents 3.49% of its overall portfolio holdings.

Number of Shares

4,569,802

Previous 4,551,556 0.4%

Holding current value

$40.2 Million

Previous $95.9 Million 44.25%

% of portfolio

3.49%

Previous 3.78%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$11.51 - $21.53 $210,011 - $392,836	18,246 Added 0.4%	4,569,802 $53.5 Million
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $9.62 Million - $19.5 Million	790,866 Added 21.03%	4,551,556 $95.9 Million
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $22.4 Million - $36.1 Million	1,734,114 Added 85.57%	3,760,690 $67.5 Million
Q2 2023 Aug 14, 2023	BUY	$17.23 - $21.71 $6.65 Million - $8.38 Million	385,851 Added 23.52%	2,026,576 $40.5 Million
Q1 2023 May 15, 2023	SELL	$18.08 - $24.55 $4.93 Million - $6.7 Million	-272,787 Reduced 14.26%	1,640,725 $31 Million
Q4 2022 Feb 14, 2023	SELL	$20.4 - $24.73 $75,480 - $91,501	-3,700 Reduced 0.19%	1,913,512 $43.4 Million
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $1.95 Million - $3.06 Million	-87,451 Reduced 4.36%	1,917,212 $50.7 Million
Q2 2022 Aug 15, 2022	BUY	$19.35 - $35.04 $536,769 - $972,009	27,740 Added 1.4%	2,004,663 $49.5 Million
Q1 2022 May 16, 2022	BUY	$24.62 - $34.31 $1.96 Million - $2.73 Million	79,700 Added 4.2%	1,976,923 $65.6 Million
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $3.34 Million - $4.46 Million	-110,778 Reduced 5.52%	1,897,223 $62 Million
Q3 2021 Nov 15, 2021	SELL	$29.09 - $45.68 $3.79 Million - $5.95 Million	-130,200 Reduced 6.09%	2,008,001 $84.2 Million
Q2 2021 Aug 16, 2021	SELL	$32.46 - $40.48 $6.56 Million - $8.18 Million	-202,112 Reduced 8.64%	2,138,201 $83.1 Million
Q1 2021 May 17, 2021	BUY	$33.61 - $49.95 $7.29 Million - $10.8 Million	216,821 Added 10.21%	2,340,313 $79.8 Million
Q4 2020 Feb 16, 2021	SELL	$26.52 - $49.35 $2.78 Million - $5.17 Million	-104,674 Reduced 4.7%	2,123,492 $96.3 Million
Q3 2020 Nov 16, 2020	SELL	$27.01 - $40.26 $232,286 - $346,236	-8,600 Reduced 0.38%	2,228,166 $61.3 Million
Q2 2020 Aug 14, 2020	SELL	$27.75 - $43.44 $2.82 Million - $4.42 Million	-101,700 Reduced 4.35%	2,236,766 $82.4 Million
Q1 2020 May 15, 2020	SELL	$21.5 - $54.2 $3.65 Million - $9.21 Million	-169,920 Reduced 6.77%	2,338,466 $75.7 Million
Q4 2019 Feb 14, 2020	BUY	$34.54 - $44.87 $5.04 Million - $6.55 Million	145,900 Added 6.18%	2,508,386 $103 Million
Q3 2019 Nov 14, 2019	BUY	$31.84 - $50.88 $30.9 Million - $49.4 Million	971,110 Added 69.79%	2,362,486 $84.1 Million
Q2 2019 Aug 14, 2019	SELL	$42.0 - $59.29 $1.22 Million - $1.72 Million	-28,966 Reduced 2.04%	1,391,376 $71.5 Million
Q1 2019 May 15, 2019	BUY	$40.82 - $62.45 $2.68 Million - $4.1 Million	65,600 Added 4.84%	1,420,342 $81.4 Million
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $11.8 Million - $22.6 Million	-301,323 Reduced 18.2%	1,354,742 $56.8 Million
Q3 2018 Nov 14, 2018	BUY	$65.0 - $82.15 $6.17 Million - $7.8 Million	94,890 Added 6.08%	1,656,065 $125 Million
Q2 2018 Aug 14, 2018	SELL	$27.2 - $74.35 $15.5 Million - $42.4 Million	-569,797 Reduced 26.74%	1,561,175 $112 Million
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $17 Million - $26.5 Million	705,700 Added 49.51%	2,130,972 $0
Q4 2017 Feb 14, 2018	SELL	$26.0 - $34.6 $6.3 Million - $8.39 Million	-242,400 Reduced 14.54%	1,425,272 $47.4 Million
Q3 2017 Nov 14, 2017	BUY	$18.0 - $32.95 $30 Million - $54.9 Million	1,667,672	1,667,672 $55 Million

Others Institutions Holding RGNX

# of Institutions

199

Shares Held

43.3M

Call Options Held

58.9K

Put Options Held

58.4K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $380M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Regenxbio Inc. Transaction History